Fig. 6.

LAMP2a-inactivation in HSCs-derived macrophage alters macrophage phenotypes and represses tumor progression.

(a) Schematic diagram describing the design of mouse Lamp2a-targeting CRISPR guideRNAs. PAM sites are shown in blue.

(b) LAMP2a expression in sg-SCR or sg-L2a transfected HSCs-derived macrophages.

(c) mRNA expression of genes related to inflammatory (blue) or immunosuppressive (red) macrophage activation was detected by qPCR in sg-SCR or sg-L2a transfected HSCs-derived macrophages. Results were represented as log2 scale, with β-actin as control.

(d) LDH release from 4T1, CT26, LL/2 cells after 24 h co-culture with gradient ratios of sg-SCR or sg-L2a transfected HSCs-derived macrophages. The percentage of cytotoxicity was calculated by maximum tumor cells LDH release control. Data were analyzed with one-way ANOVA tests.

(e) The procedures of LAMP2a-inactivating HSCs chimera establishment.

(f) and (g) Tumor weights (f) and LAMP2a expression in TAMs (g) of LAMP2a-inactivating or wild type bone marrow chimera PyMT mice.

(h) and (i) Cell population of mTAMs, MDSCs (h) and IMCs (i) from LAMP2a-inactivating or wild type bone marrow chimera PyMT mice.

Data are represented as mean ± SD, with Student's t-tests unless noted. *p < 0·05, **p < 0·01, ***p < 0·001, ns, no significance. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)